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background: Intensity modulated radiotherapy (IMrT) has the perceived advantage of function preservation by reduction 
of toxicities in the treatment of laryngo-pharyngeal malignancies. The aim of the study was to assess changes in dysphagia 
from baseline (i.e. prior to start of treatment) at three and six months post treatment in patients with laryngo-pharyngeal 
malignancies treated with radical radiotherapy ± chemotherapy. Functional assessment of other structures involved in swal-
lowing was also studied. 
Materials and methods: 40 patients were sampled consecutively. 33 were available for final analysis. Dysphagia, laryngeal 
edema, xerostomia and voice of patients were assessed at baseline and at three and six months after treatment. radiation 
was delivered with simultaneous integrated boost (sIB) using volumetric modulated radiation therapy (VMaT). concurrent 
chemotherapy was three weekly cisplatin 100 mg/m2.
results: proportion of patients with dysphagia rose significantly from 45.5% before the start of treatment to 57.6% at three 
months and 60.6% at six months post treatment (p = 0.019). 67% patients received chemotherapy and addition of chemo-
therapy had a significant correlation with dysphagia (p = 0.05, r = –0.336). severity of dysphagia at three and six months cor-
related significantly with the mean dose received by the superior constrictors (p = 0.003, r = 0.508 and p = 0.024, r = 0.391) 
and oral cavity (p = 0.001, r = 0.558 and p = 0.003, r = 0.501). There was a significant worsening in laryngeal edema at three 
and six months post treatment (p < 0.01) when compared to the pre-treatment examination findings with 60.6% of patients 
having grade two edema at six months. significant fall in the mean spoken fundamental frequency from baseline was seen at 
6 months (p = 0.04), mean fall was 21.3 hz (95% cI: 1.5–41 hz) with significant increase in roughness of voice post treatment 
(p = 0.01). 
conclusion: There was progressive worsening in dysphagia, laryngeal edema and voice in laryngo-pharyngeal malignancies 
post radical radiotherapy ± chemotherapy. 
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Introduction
Chemoradiation has a central role in the treat-
ment of locally advanced laryngo-pharyngeal ma-
lignancies with function preservation as one of the 
main advantages [1]. However, treatment related 
toxicities remain a major concern for patients re-
ceiving radical chemoradiation [2]. Modern tech-
niques of radiation delivery like intensity modu-
lated radiotherapy (IMRT) and volumetric modu-
lated arc therapy (VMAT) have reduced treatment 
related toxicities [3, 4]. These techniques also allow 
for simultaneous integrated boost (SIB) or “dose 
painting” — delivery of higher dose per fraction to 
the tumour and standard dose per fraction to areas 
at intermediate and low risk [4, 5]. 
Despite the use of modern treatment delivery 
techniques, dysphagia remains one of the most dis-
tressing acute as well as late toxicity associated with 
radical radiation therapy in head and neck cancers 
[7]. Swallowing being a complex process has many 
structures playing important roles in its proper ex-
ecution, such as the parotids, larynx, oral cavity 
and constrictor muscles [8]. Impaired functioning 
of each of these organs as reflected by the develop-
ment of xerostomia, laryngeal edema etc. would 
also contribute to the changes in dysphagia after 
treatment [3, 9]. In this study, we aimed to evaluate 
the changes in dysphagia, laryngeal edema, xero-
stomia and voice after treatment with radical radio-
therapy delivered by VMAT with SIB ± concurrent 
chemotherapy in laryngo-pharyngeal primaries 
and correlate the toxicities with doses received by 
OARs. 
Materials and methods
This prospective observational study included 
consecutive patients with pathologically confirmed 
squamous cell carcinomas of oropharynx, hypo-
pharynx and larynx attending the radiation on-
cology outpatient department of our center from 
January 2017 to August 2018. Patient recruitment 
details are given in Figure 1. Primary treatment 
was planned with radical radiation or chemora-
diation after discussion in a multidisciplinary tu-
mour board consisting of head and neck surgery, 
radiation oncology, radiology and head and neck 
physiotherapy specialists. Patients with a poor per-
formance status (Eastern Cooperative Oncology 
Group performance score ≥ 3), those who have 
previously undergone head and neck surgery, ra-
diotherapy or systemic chemotherapy and those 
dependent on tracheostomy tubes were excluded. 
Staging was done according to the AJCC 7th edition 
manual. The study was approved by the Institute 
ethics committee. Written informed consent was 
given by all patients.
70 head and neck cancer patients
planned for radical treatment were screened
40 patients were included in the study
33 patients completed treatment
and planned follow-up at 6 months
30 patients did not meet
the inclusion criteria
3 patients did not receive
treatment after planning
3 patients defaulted 
and 1 progressed on treatment
37 patients were started on treatment
Figure 1. strobe diagram
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Treatment
Patients were immobilized using a thermoplastic 
immobilization system. After Contrast enhanced 
CT Simulation, gross tumour delineation was 
done based on information from the simulation 
scans, endoscopic findings and review of diagnostic 
imaging. Treatment planning was done with the 
ECLIPSE planning system 10.0 (Varian Medical 
Systems, Palo Alto, CA). The prescription was 66 
Gy in 30 fractions to the high risk (gross disease 
and nodes involved with five mm margins), 60 Gy 
in 30 fractions to the intermediate risk (nodal sta-
tions involved with one cm margin to the gross 
disease), and 54 Gy in 30 fractions to the low risk 
planning target volumes (PTV). Radiation was de-
livered as SIB using VMAT. Organs at risk (OAR), 
such as the spinal cord, brainstem, three pharyngeal 
constrictors, larynx, oral cavity including the minor 
salivary glands and parotids, were contoured ac-
cording to standard published guidelines [10–12]. 
Constraints for OARs were largely based on Quan-
titative Analyses of Normal Tissue Effects in the 
Clinic (QUANTEC) and standard institutional pro-
tocols [13]. Plans were optimized such that 95% of 
PTV was covered by the prescription dose. During 
optimisation and plan evaluation, PTV coverage 
was not compromised at the cost of sparing an 
OAR. Offline image verification was done and No 
Action Level (NAL protocol) was followed for cal-
culating setup errors. Once weekly cone beam CT 
(CBCT) was taken after correction of errors for 
treatment verification.
Concurrent chemotherapy administered was 
three weekly cisplatin 100 mg/m2. Patients were 
reviewed weekly during the course of radiation for 
assessment of toxicities.
endpoints
The primary endpoint was to assess the change in 
the severity of dysphagia from baseline (i.e. prior to 
start of treatment) and at three and six months post 
treatment. The third and sixth month time points 
were chosen to represent acute and late dysphagia, 
respectively [14]. Any dysphagia interfering with 
normal food intake was taken as significant (grade 
one and above). 
Secondary endpoints included the assessment 
of toxicities of other structures (eg. larynx, salivary 
glands) involved in the process of swallowing which 
included laryngeal edema, voice changes and xero-
stomia. Correlation of toxicities with doses received 
by different OARs was done. Mean doses were se-
lected for correlation of toxicities as the OARs dis-
cussed were mostly parallel structures whose toxici-
ties correlated well with mean doses [13]. Toxicities 
were graded by the European organization for re-
search and treatment of cancer (EORTC)/Radia-
tion Therapy Oncology Group (RTOG) Radiation 
morbidity scoring criteria [15]. 
Voice analysis was based on recordings which 
included a standard passage in vernacular and three 
sustained vowels (a, i and u) repeated thrice. Maxi-
mum phonation times for each vowel were noted. 
Sony F-V 120 unidirectional microphone was used 
for recording. Recorded samples were analyzed us-
ing the VAGMI version 8.1 voice processing soft-
ware. Fundamental frequencies of the three vowels 
and mean spoken fundamental frequency from the 
recorded passage were obtained. 
Perceptual assessment of voice was done by 
the GRBAS scale of the Japan society of Logope-
dics and Phoniatrics. Scores of zero, one, two, or 
three were given for each of the five voice quali-
ties; Grade, Roughness, Breathiness, Asthenia, and 
Strain, where zero was normal and three was severe 
impairment [16]. Scoring was done by a trained 
speech language pathologist not privy to the patient 
status or voice sample information.
A questionnaire based evaluation of xerostomia 
at three time points was done [17]. Subjects rated 
eight symptoms on an 11-point ordinal Likert scale 
from zero to ten, with higher scores indicating 
greater discomfort due to dryness. Each item score 
was added, to get the final score ranging between 
zero and eighty. Higher scores represented greater 
levels of xerostomia. Weights of the patients were 
taken prior to the start of treatment and at three 
and six months after completion of treatment.
statistical analysis
We hypothesised that there will be an increase 
in the proportion of patients with dysphagia from 
baseline post radical radiation ± chemotherapy at 
six months. The minimum expected proportion of 
patients reporting any degree of dysphagia was 0.77 
[18]. Sample size was estimated to be 40 using the 
formula for estimating single proportion at 5% level 
of significance, 20% precision and 30% dropout. 
All statistical tests considered p < .05 as statistically 
significant.
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SPSS version 19 was used for analysis. Non-para-
metric parameters were compared using the Fried-
man test. Continuous variables were analysed us-
ing ANOVA. Post hoc analysis with the Bonferroni 
correction was done when results were significant. 
Spearman’s correlation coefficient was used to iden-
tify the correlation of grades of toxicities with doses 
received to OARs.
results
Baseline characteristics of the patients are given 
in Table 1. The mean (SD) cumulative dose of cis-
platin received was 233 (68) mg. 72% of the patients 
received at least two cycles of chemotherapy. The 
mean (SD) duration of radiation course was 51 
(11.0) days.
There was a significant correlation between tu-
mour site and mean doses to the superior constric-
tors (p < 0.001, r = 0.613), oral cavity (p < 0.001, 
r = 0.852) and larynx (p < 0.001, r = 0.649). The site 
wise distribution of the doses received by OARs is 
given in Table 2. 
Dysphagia
The proportion of patients with dysphagia at 
baseline was 45.5%. At three months post treat-
ment it rose to 57.6% and at six months it became 
60.6%. The change in severity of dysphagia with 
time (Fig. 2) was significant (p = 0.019). Post hoc 
analysis revealed the difference to be significant 
between baseline and six months post treatment 
(p = 0.036). 36% (n = 12) patients had a worsening 
of dysphagia, 9% (n = 3) had an improvement and 
55% (n = 18) did not have any change in the severi-
ty of dysphagia at six months compared to baseline. 
There was a significant correlation between dyspha-
gia at six months and the addition of chemotherapy 
(p = 0.05, r = –0.336). 41% of patients who received 
chemotherapy had a worsening of dysphagia at six 
months compared to 27% patients who did not re-
ceive chemotherapy.
 Mean dose received by the superior constrictors 
correlated significantly with dysphagia at three and 
six months post treatment. (p = 0.003, r = 0.508& 
p = 0.024, r = 0.391 respectively). All patients 
with ≥ grade two dysphagia at three and six months 
post treatment received mean dose > 50Gy to the 
superior constrictor. There was no correlation with 
the severity of dysphagia and mean dose to the 
middle and inferior constrictors.
Mean dose to the oral cavity correlated with 
the severity of dysphagia at three and six months 
(p = 0.001, r = 0.558 and p = 0.003, r = 0.501 re-
spectively). Almost all patients with ≥ grade two 
dysphagia at six months received mean dose >35 
Gy to the oral cavity.
Laryngeal edema
Proportion of patients presenting with grade two 
laryngeal edema rose from 3% at baseline to 24% 
at three months and 61% at six months (Fig. 3). 
The difference in grades of laryngeal edema from 
baseline were significant at three and six months 
(p < 0.001 for both). All patients developing grade 
two laryngeal edema at six months received mean 
laryngeal dose more than 55 Gy. There was no cor-
relation with the severity of dysphagia and laryn-
geal edema post treatment.
table 1. principal characteristics of the patients (n = 33)
Factor Description 
Age
age (years) Mean = 60.6, sD = 8.9
sex
Male 91% (n = 30)
Female 9% (n = 3)
smoking
Yes 85% (n = 28)
No 15% (n = 5)
t stage
T1 9% (n = 3)
T2 9% (n = 3)
T3 39.4% (n = 13)
T4 42.5% (n = 14)
N stage
N0 15% (n = 5)
N1 48.4% (n = 16)
N2 36.3% (n = 13)
stagewise distibution of site 
Oropharynx: n, (stages 1/2/3/4) 13, (1/1/3/8)
hypopharnx: n, (stage 1/2/3/4) 4, (0/0/2/2)
Larynx :n, (stage 1/2/3/4) 16, (2/1/9/4)
chemotherapy
Yes 67% (n = 22)
No 33% (n = 11)
sD — standard deviation
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Voice changes
There was a significant fall in fundamental fre-
quencies of the vowels a, i and u from baseline 
(Tab. 3). Post hoc analysis showed a significant dif-
ference in fundamental frequencies for a and i at 
three months post treatment when compared to the 
values at baseline (p < 0.001 and p = 0.016, respec-
tively). Mean fall in fundamental frequency for a at 
table 2. site wise distribution of doses to the organ at risks (Oars) (n = 33)
OAR
Median of the mean dose to OARs in Gy (Q3–Q1)
Oropharynx Hypopharynx Larynx
superior constrictor 67.3 (68.3–64.9) 63.8 (67.3-57.8) 55.6 (60.9–35.9)
Middle constrictor 67.2 (68.1–58.4) 67.9 (68.2–66.9) 66.8 (67.7–64.6)
Inferior constrictor 54.6 (60.4–51.9) 67.8 (67.9–66.8) 66.5 (67.7–64.3)
Larynx 55.8 (61.7–52.5) 67.9 (68.5–67.0) 66.9 (67.9–65 )
Oral cavity 61.9 (64.7–55.4) 38  (42.7–35.5) 20.7 (34.2–16.5)
parotids 26.4 (32.2–23.4) 31.5 (45.5–29.1) 22.2 (25.3-20.2)
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Figure 3. change in severity of laryngeal edema with time
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three months was 15.49 Hz (95% CI: 8.5–22.4 Hz) 
and for i at three months it was 15.06 Hz (95% CI: 
2.3–27.8 Hz). The fall in fundamental frequency for 
a was significant at six months as well when com-
pared to the baseline (p = 0.008), with mean fall of 
18.14 Hz (95% CI: 4–32 Hz). 
There was a significant fall in the mean spoken 
fundamental frequency (Tab. 3). Post hoc analy-
sis showed a significant change from baseline to 
six months (p = 0.04) with mean fall of 21.3 Hz 
(95% CI: 1.5–41Hz) and from three months to six 
months (p = 0.023), with mean fall of 14 Hz (95% 
CI: 1.5–26.5Hz).
Perceptual assessment of voice by GRBAS scal-
ing revealed significant changes in the subjective 
parameter of roughness post treatment (p = 0.01). 
Post hoc analysis revealed a significant differ-
ence in roughness between three and six months 
(p = 0.003) with nearly 50% of patients having 
increased roughness. There was a non-significant 
increase in the maximum phonation times of the 
vowels at three months from baseline with decrease 
from three to six months.
Other toxicities
There was a worsening of xerostomia scores at 
three months post treatment with a significant im-
provement in nearly all cases at six months (Tab. 
3, p < 0.001 for both). Xerostomia scores at three 
months correlated significantly with mean dose to 
the oral cavity and the parotids (p = 0.002, r = 0.531 
and p = 0.047, r = 0.34, respectively). Three patients 
developed grade three dermatitis and two patients 
developed grade three oral mucositis during treat-
ment. Addition of chemotherapy did not have any 
significant impact on mucositis. 
More than 50% of patients had weight loss 
of ≥ five kg from the baseline at three and six 
months after treatment, (Tab. 3, p < 0.001 for both). 
Mean weight loss at six months was 5.03 kg with 
95% CI (3–7 kg).
Discussion 
Dysphagia remains a dreaded complication after 
radical chemoradiotherapy. The identification of 
dysphagia and aspiration related structures (DARS) 
by Eisbruch et al. [19] has been pivotal in limiting 
this toxicity. The results of the DARS study by Nut-
ting et al. [20] clarified the advantage of limiting the 
mean doses to key swallowing structures like the 
pharyngeal constrictors with a significant reduction 
in patient reported swallowing difficulties in the 
dysphagia optimised IMRT (Do-IMRT) arm. 
Changes in dysphagia with time for head and 
neck malignancies treated non-surgically have 
been evaluated in similar studies. Roe et al21 
showed a significant decrease in the swallow per-
formance at three months post treatment. Wilson 
et al.22  demonstrated 18% deterioration in MDADI 
(M.D. Anderson Dysphagia Inventory) scores three 
months post treatment The proportion of patients 
with ≥ grade two dysphagia rose from 0% at base-
line to 41% at the end of three months in an identi-
cal setting by Mazzola et al. [14] as well. 
However, the results of our study showed that 
dysphagia continued to worsen steadily from base-
line at six months post treatment as well with the 
proportion of patients with ≥ grade two dysphagia 
reaching 33% at six months. This contrasts with 
the above studies which showed a plateauing of the 
swallowing difficulties with even a trend for im-
provement at six months when compared to three 
months [14, 21, 22]. The inability to meet the dose 
constraints of the OARs, inclusion of higher pro-
portion of patients with dysphagia at the onset of 
treatment (45.5% vs. 0%) [14, 22], higher propor-
tion of concurrent chemotherapy (67% vs. 54%) 
table 3. change in parameters studied with time (n = 33)
Factor studied Baseline 3 months 6 months p–value
FF of vowel a in Hz, mean (sD) 137.3 (34.2) 121.8 (28.5) 119.1 (26.5) < 0.001
FF of vowel i in Hz, mean (sD) 149.9 (43.8) 134.8 (30) 132.9 (33.4) 0.02
FF of vowel u Hz, mean (sD) 149.8(35.6) 133.7 (26.5) 136.5 (31.1) 0.009
MsFF in hz, mean (sD) 142.4 (43.5) 135.1 (27.1) 121.1 (23.2) 0.017
Xerostomia score, median (Q3–Q1) 0 (5–0) 25(50–3) 14 (41–0) < 0.001
Weight in kg, mean (sD) 55 (12.4) 50.1 (12) 49.9 (12) < 0.001
FF — fundamental frequency; Q1 — first quartile; Q3 — third quartile; MsFF — mean spoken fundamental frequency; sD — standard deviation
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[14] and higher proportion of smokers in the study 
population (85% vs. 57%) [21, 23] could have con-
tributed to the increase in proportion of patients 
with ≥ grade two dysphagia at six months. The fall 
in the weight of patients observed after completion 
of treatment also serves as a pointer to the progres-
sive worsening of dysphagia that is observed three 
and six months after treatment [24]. 
Thus, in this study, treatment related toxicities 
continued to be a matter of concern with majority 
of patients having difficulty in the ability to take 
normal diet even at six months post treatment.
The severity of dysphagia post treatment cor-
related significantly with the dose to the superior 
constrictors. Nearly all patients with ≥ grade two 
dysphagia at six months had mean dose > 50 Gy to 
the superior constrictor. This validates the results 
of a recent metaanalysis which predicted higher 
occurrence of dysphagia with mean doses in excess 
of 50 Gy to the pharyngeal constrictor muscles [25]. 
The study by Mazola et al. [14] also estimated the 
odds ratio of developing dysphagia at six months to 
be 9.3 when the mean dose to the superior constric-
tors exceeded 50 Gy. 
The tongue along with secretions from the minor 
salivary glands plays a key role in the oral prepara-
tory phase and the oral phase of swallowing. Dam-
age to these structures after treatment could be the 
reason for the correlation between dysphagia and 
xerostomia scores with mean doses to the oral cav-
ity [26]. The observations made here regarding the 
occurrence of progressive worsening of dysphagia 
when mean doses to the oral cavity exceeded 35 
Gy could also serve as an indicator for prescription 
of mean dose constraints to the oral cavity during 
treatment planning.
The role of DARS in producing dysphagia is also 
influenced by the site of the primary as is observed 
in our study by virtue of the doses received by the 
OARs [27]. The mean dose to the oral cavity was lim-
ited to less than 35 Gy in more than half of non-oro-
pharyngeal primaries and in nearly half of laryngeal 
primaries, the mean dose to the superior constrictors 
was limited to less than 50 Gy. Thus, the site of the 
primary also has an important role in practical at-
tainment of constraints to the different OARs. 
The rising trend of laryngeal edema at three and 
six months post treatment in head and neck malig-
nancies receiving radiotherapy is also seen in the 
study by Sanguineti et al. [28]. However the mean 
dose (SD) received by the larynx in our study was 
62.6 (6.3) Gy which was well in excess of the rec-
ommended constraints (mean dose < 44 Gy) for 
laryngeal edema rates of less than 20%. Progres-
sive edema of the larynx post treatment may result 
in long term adverse effects involving phonation, 
swallowing etc. [9, 25]. This, along with other fac-
tors like altered microcirculation, fibrosis and neu-
romuscular fold weakness could result in the fall in 
fundamental frequencies as observed [29]. 
Voice is a multidimensional construct forming 
an important part of a person’s identity. Fundamen-
tal frequency is an objective measure of the pitch 
of the voice [30]. The changes in voice as a result 
of development of laryngeal edema as well as the 
changes in pitch secondary to variations in the fun-
damental frequencies can change self-perception as 
well as how the person is perceived by others. Thus, 
it has the potential to affect the social, emotional 
and overall quality of life of the patient [31]. 
The changes in fundamental frequencies and 
subjective voice parameters in both non-laryngeal 
and laryngeal primaries receiving radical chemora-
diation were assessed by Paleri et al. [29] and Karls-
sen et al. [30], respectively., The fall in frequencies 
and the worsening in subjective voice assessment 
seen in our study were common to those studies 
as well. The post treatment effects in vocal folds as 
a result of late effects of radiotherapy could be the 
prime reason for worsening of roughness observed 
here as described in the study by Karlssen et al. [33]. 
The progressive worsening of toxicities at six 
months post treatment could limit the perceived 
advantage of function preservation with upfront 
radical radiation ± chemotherapy. The results of the 
DARS study have clarified the impact of pharyngeal 
muscle sparing in improving dysphagia in patients 
with head and neck cancer [20]. Thus, treatment 
goals to limit the volume of key structures receiv-
ing doses in excess of recommended constraints 
need to be explored. This may include routine use 
of Do-IMRT, adaptive radiotherapy and induction 
chemotherapy with techniques of radiation delivery 
like SIB with VMAT in laryngopharyngeal tumours, 
especially in the locally advanced setting [33, 34]. 
Novelty
This study demonstrated significant continuing 
worsening of dysphagia from baseline at six months 
post radical radiation treatment along with pro-
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gressive worsening of laryngeal edema and subjec-
tive and objective voice parameters. The identifica-
tion of key structures like the oral cavity and the 
superior constrictors in limiting the occurrence of 
treatment related dysphagia with validation of the 
current recommendations for dose constraints have 
also been done. 
Limitations
Registration of MRI with planning CT was not 
done for OAR delineation. Majority of the patients 
belonged to the locally advanced stage with large pri-
maries and, hence, the constraints to the OARs could 
not be met. HPV status of oropharyngeal tumours 
was not assessed. The limited duration of follow up 
post treatment was a deterrent in identifying possible 
improvements in dysphagia with passage of time.
conclusion
The observed long term worsening of dyspha-
gia, laryngeal edema and voice from baseline at 6 
months post treatment could necessitate the use of 
routine dysphagia optimised-IMRT and/or adap-
tive radiotherapy for function preservation. The im-
provements in functional outcomes with addition 
of induction chemotherapy to radical radiothera-
py ± concurrent chemotherapy when compared to 
upfront chemoradiation, especially in locally ad-
vanced laryngo-pharyngeal tumours, also need to 
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